Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma

Radiology

Volumn 256, Issue 2, 2010, Pages 575-584

  Mangla, Rajiv ^a   Singh, Gurshawn ^a   Ziegelitz, Doerthe ^a,b   Milano, Michael T ^a   Korones, David N ^a   Zhong, Jianhui ^a   Ekholm, Sven E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADULT; AGED; ARTICLE; BRAIN BLOOD VOLUME; BRAIN PERFUSION; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME; ANALOGS AND DERIVATIVES; BLOOD VOLUME; BRAIN NEOPLASMS; COMPUTER ASSISTED RADIOTHERAPY; INCIDENCE; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD VOLUME; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955128785     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091440     Document Type: Article

References (34)

1. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85(9):704-710.
2. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to- N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19(5):546-554.
3. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26(10):2466-2474.
4. Saraswathy S, Crawford FW, Lamborn KR, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009;91(1):69-81.
5. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-oncol 2008;10(3):361-367.
6. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
7. Aronen HJ, Perkiö J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 2002;12(4):501-523. (Pubitemid 36015488)
8. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*- weighted MR imaging. Radiology 1999;211(3):791-798. (Pubitemid 29249482)
9. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24(10):1989-1998. (Pubitemid 37444849)
10. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - prediction of patient clinical response. Radiology 2006;238(2):658-667. (Pubitemid 43134379)
11. Cao Y, Tsien CI, Nagesh V, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006;64(3):876-885.
12. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-498.
13. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69(13):5296-5300.
14. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-oncol 2006;8(1):38-46. (Pubitemid 43154449)
15. Broglio KR, Berry DA. Detecting an over-all survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101(23):1642- 1649.
16. Thilmann O. LUPE: an extensible modular framework for evaluation of DSC-acquired perfusion images. MAGMA 2004;16 (electronic suppl 1):537.
17. Haselhorst R, Kappos L, Bilecen D, et al. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging 2000;11(5):495-505. (Pubitemid 30252836)
18. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-1280.
19. Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009;192(2):W45-W52.
20. Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 2006;24(9):1131-1142. (Pubitemid 44635065)
21. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25(26):4104-4109. (Pubitemid 47495868)
22. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21(5):901-909.
23. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21(5):881-890. (Pubitemid 30262835)
24. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008;247(1):170-178.
25. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25(2):214-221.
26. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology Magn Reson Med 2003;49(5):848-855.
27. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6(6):2189-2200.
28. Grossman RI, Hecht-Leavitt CM, Evans SM, et al. Experimental radiation injury: combined MR imaging and spectroscopy. Radiology 1988;169(2):305-309.
29. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27(4):859-867.
30. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249(2):601-613.
31. Di Chiro G, Fulham MJ. Virchow's shackles: can PET-FDG challenge tumor histology? AJNR Am J Neuroradiol 1993;14(3):524-527.
32. Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79(1):115-126.
33. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996.
34. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003.